Dipyridamole is a phosphodiesterase inhibitor used to prevent postoperative thromboembolic events. A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells.
- Mechanism
- Curator reviewed
Dipyridamole likely inhibits both adenosine deaminase and phosphodiesterase, preventing the degradation of cAMP, an inhibitor of platelet function. This elevation in cAMP blocks the release of arachidonic acid from membrane phospholipids and reduces thromboxane A2 activity. Dipyridamole also directly stimulates the release of prostacyclin, which induces adenylate cyclase activity, thereby raising the intraplatelet concentration of cAMP and further inhibiting platelet aggregation.
- Primary indication
- For as an adjunct to coumarin anticoagulants in the prevention of postoperative thromboembolic complications of cardiac valve replacement and also used in prevention of angina.Curator reviewed · 11 structured indications
- Formula / weight
- C24H40N8O4 · 504.6256 g/mol (avg)
- First approval
- Canada, 2000 · United States, 1980
- Also known as
- Dipyridamine · Dipyudamine · Dypyridamol
- Code names
- NSC-515776 · USAF GE-12
- Brand names
Resolves to
IZEKFCXSFNUWAM-UHFFFAOYSA-NSMILESOCCN(CCO)C1=NC2=C(N=C(N=C2N2CCCCC2)N(CCO)CCO)C(=N1)N1CCCCC1What you can answer from here — as of September 23, 2026
Which drugs share a target with Dipyridamole, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account